PharmaResearch Products
PharmaResearch Products is a South Korea-based KOSDAQ-listed regenerative medicine company that develops PDRN-based aesthetic injectables, consumer skincare (REJURAN Cosmetics), and an FDA-cleared nano anticancer drug candidate (PRD-101) using its proprietary DOT DNA optimization technology, selling to aesthetic practitioners and global retail partners including Sephora.
- Company typePrivate
- Founded1993
- HeadquartersGangneung, South Korea
- Headcount101–250
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What PharmaResearch Products does
PharmaResearch Products Co., Ltd. is a South Korea-based, KOSDAQ-listed (214450) regenerative medicine company founded in 1993 that develops, manufactures, and commercializes PDRN (Polydeoxyribonucleotide)-based products for aesthetic, dermatological, and emerging oncology applications. The company's core technology is its proprietary DOT (DNA Optimizing Technology) platform, which extracts DNA from salmon germ cells and optimizes it as a regenerative active substance, deployed through multiple delivery systems including PLGA nanoparticles, lipid nanoparticles, microneedles, exosome encapsulation, and chitosan carriers. PharmaResearch holds an 88.0% share of the PDRN material source market and 70.3% share of single-ingredient injectables as of 2025, and its branded REJURAN franchise is recognized as Korea's No.1 medical aesthetic brand.
The company operates a dual-track business model spanning professional aesthetics and consumer skincare. In the professional channel, REJURAN PN-based skin boosters are sold to aesthetic practitioners, with expansion underway across Western Europe (via Laboratoires VIVACY), Brazil (via DermaDream), and existing presence in Chile and Peru. In the consumer channel, REJURAN Cosmetics products, powered by the patented c-PDRN ingredient, launched at Sephora U.S. (approximately 380 stores and sephora.com) in March 2026, supplemented by Amazon and TikTok Shop distribution. A third leg, the FDA IND-cleared nano anticancer drug candidate PRD-101, entered Phase 1 trials in February 2026 for locally advanced or metastatic solid tumors, representing entry into oncology using the DOT drug delivery platform.
Revenue mechanics are diversified across multiple channels and geographies, though the company is in a capital-intensive expansion phase. It raised KRW 200 billion (~$144M) from CVC Capital Partners in 2026, acquired TuringBio (AI digital therapeutics) in 2024 and announced the acquisition of CG USA (FDA-registered Los Angeles cosmetics manufacturer) in June 2026 to localize U.S. manufacturing. The company maintains operations in South Korea (Gangneung, Seoul) and the United States (Los Angeles), with 101-250 employees, and is led by CEOs Jung Sangsoo and Ahn Wonjun. The export business has grown approximately 5x over recent years, with U.S. exports surging over 400% YoY for three consecutive quarters in 2023.
PharmaResearch Products firmographics
Firmographics- Name
- PharmaResearch Products
- Legal name
- PharmaResearch Co., Ltd.
- Website
- https://pharmaresearch.co.kr
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- PharmaResearch Products is a South Korea-based KOSDAQ-listed regenerative medicine company that develops PDRN-based aesthetic injectables, consumer skincare (REJURAN Cosmetics), and an FDA-cleared nano anticancer drug candidate (PRD-101) using its proprietary DOT DNA optimization technology, selling to aesthetic practitioners and global retail partners including Sephora.
- Ownership category
- akta.pro rank
PharmaResearch Products industry classification
Industry- Product category
- Regenerative Medicine Pharmaceuticals and Derma-Cosmetics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242), Health and Personal Care Retailers (456)
- SIC
- Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
Keywords
Where PharmaResearch Products is headquartered
LocationHeadquarters
- HQ city
- Gangneung
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
PharmaResearch Products business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel
Revenue model
- PDRN Injectables: Sales of PDRN-based injectable skin boosters for aesthetic medicine, with salmon DNA-derived PDRN as primary material source at 88.0% market share in 2025. Single-ingredient injectables dominate with 70.3% market share.
- REJURAN Cosmetics (Consumer Skincare): Consumer derma-cosmetic skincare products sold through Sephora retail and e-commerce channels including Amazon and TikTok Shop. Revenue from Korea-manufactured products with plans for local U.S. manufacturing via CG USA acquisition.
- Nano Anticancer Drug (PRD-101): Phase 1 clinical trial stage nano anticancer drug candidate leveraging proprietary DOT drug delivery platform. Revenue potential pending regulatory approval.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels4 records
PharmaResearch Products product offering
Product offeringCore offering
PharmaResearch Products is a biopharmaceutical company that develops, manufactures, and sells PDRN-based regenerative medicine products using its proprietary DNA Optimizing Technology (DOT) platform. Its commercial portfolio includes the REJURAN line of PN-based skin booster injectables for medical aesthetic practitioners and the REJURAN Cosmetics derma-cosmetic consumer skincare line featuring c-PDRN-based ampoules, creams, and masks sold through retail and e-commerce channels. The company is also developing PRD-101, a next-generation nano anticancer drug candidate leveraging the DOT drug delivery platform that received FDA IND clearance for Phase 1 clinical trials.
Product overview
PharmaResearch Products is a South Korea-based regenerative medicine company offering a dual product portfolio comprising pharmaceutical and derma-cosmetic offerings. The core pharmaceutical line includes REJURAN, a PN-based skin booster leveraging the proprietary DOT™ DNA Optimizing Technology, and PRD-101, a nano anticancer drug candidate in clinical development. The consumer-facing derma-cosmetic line is branded as REJURAN Cosmetics, featuring c-PDRN-based skincare products including ampoules and creams, distributed through Sephora, Amazon, and other retail channels. The company operates manufacturing facilities in South Korea and is expanding into the U.S. market through the planned acquisition of CG USA.
Differentiator
Problem solved
Functional benefit
Brands
- REJURAN Cosmetics: Korea's No.1 medical aesthetic brand developed by PharmaResearch, powered by patented c-PDRN ingredient derived from sustainably sourced salmon DNA. Products include Turnover Ampoule, Dual Effect Ampoule, and other science-led skincare products available at Sephora and Amazon.
- REJURAN
Products and services
- REJURAN PN-based skin booster product for aesthetic and regenerative medicine applications utilizing PharmaResearch's proprietary DOT™ DNA Optimizing Technology. Marketed to healthcare professionals for clinical applications in anti-aging, skin rejuvenation, and regenerative treatments for aesthetic medicine practitioners.
- REJURAN Cosmetics Consumer derma-cosmetic skincare line powered by patented c-PDRN ingredient derived from sustainably sourced salmon DNA. Includes hero products such as REJURAN Turnover Ampoule, Dual Effect Ampoule, Dual Effect Ampoule In Mask, and Pore Tightening Cream, distributed through Sephora, Amazon, and TikTok Shop for retail consumers seeking science-led skincare.
- PRD-101 Next-generation nano anticancer drug candidate developed using PharmaResearch's proprietary nucleotide-based DOT™ drug delivery platform. Currently in Phase 1 clinical trials targeting patients with locally advanced or metastatic solid tumors across up to seven U.S. clinical sites.
- REJURAN Pore Tightening Cream New consumer skincare product addition to the REJURAN Cosmetics line focused on pore tightening, leveraging patented c-PDRN ingredient derived from salmon DNA for at-home skincare applications.
Quantifiable outcome
- Over 400% year-over-year US export growth for three consecutive quarters in 2023
- +2 more outcomes
Companies that use PharmaResearch Products
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
PharmaResearch Products technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PharmaResearch Products partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- CG USA (Cosmetic Group USA)corePharmaResearch signed agreement to acquire CG USA, a California-based cosmetics OEM and ODM manufacturer with FDA-registered facility in Los Angeles. The acquisition establishes local manufacturing base for REJURAN Cosmetics in North America, enabling improved supply chain efficiency, logistics, and distribution. CG USA provides capabilities spanning product planning, formula development, manufacturing, filling, packaging and quality control. Founded in 1986, CG USA holds ISO 22716 certification and provides OEM/ODM services to cosmetics brands.
- Cosmo Group Inc.minorTransaction advisor for the CG USA acquisition. Financial terms were not disclosed.
- Laboratoires VIVACYcorePartnership to co-develop covalently crosslinked HA-PDRN combination injectables projected to potentially become the clinical reference standard for PDRN skin boosters in the EU market. Laboratoires VIVACY serves as European distribution partner, supporting PharmaResearch's five-market Western Europe expansion across Benelux, UK, Switzerland, Italy, Poland, France, and Germany.
- ConnectsminorPharmaResearch joined as strategic investor in Connects' KRW 15 billion Series C funding round. Partnership combines Connects' recombinant protein technology with PharmaResearch's global commercialization capabilities. Funds support CNT201 development for Dupuytren's contracture treatment with plans to expand indications to include cellulitis.
- DermaDreamcoreExclusive supply agreement for Rejuran product signed at IMCAS World 2026 in Paris. DermaDream serves as exclusive distribution partner in Brazil, leveraging established sales network and regulatory expertise. PharmaResearch views Brazil as a key strategic market in Latin America, building on existing experience in Chile and Peru.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
PharmaResearch Products competitors and assessment
Company assessmentDirect peers
- Laboratoires VIVACY: VIVACY is a French developer of hyaluronic acid-based injectables (Stylage) that partners with PharmaResearch on covalently crosslinked HA-PDRN combination injectables. Directly comparable as a specialized regenerative/aesthetic injectable partner with overlapping customer channel in EU.
- Hugel, Inc. Hugel is a South Korean biopharmaceutical company with a leading aesthetic injectable business (Botulax, Dermalax HA fillers) and global distribution. Directly comparable to PharmaResearch as a Korean-listed aesthetic medicine company using proprietary bio-ingredients across clinical injectables and derma-cosmetics.
- Medytox: Medytox is a Korean-listed biopharma specializing in botulinum toxin and hyaluronic acid fillers for medical aesthetics. Comparable to PharmaResearch in product category (injectable regenerative/aesthetic), customer base (clinicians and aesthetic practitioners), and Korean public-company profile with global commercial build-out.
- Teoxane Laboratories: Teoxane is a Swiss HA filler specialist (Teosyal RHA range) with global aesthetic distribution. Comparable to PharmaResearch in specializing in regenerative HA-based injectables targeting aesthetic practitioners and competing in the EU markets where REJURAN is expanding.
Broad incumbents
- Galderma: Galderma is a global dermatology-focused company with a deep aesthetic injectables portfolio (Restylane, Sculptra, Dysport) plus derma-cosmetics. Comparable to PharmaResearch in combining professional injectables with consumer skincare and targeting the same aesthetic dermatology customer.
- AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics unit (Botox, Juvéderm, CoolSculpting, SkinMedica) is the global aesthetic market leader. Comparable to PharmaResearch as the dominant incumbent defining clinical and retail standards PharmaResearch must compete against, especially with REJURAN at Sephora.
- Dermalogica (Unilever): Dermalogica is a professional skincare brand distributed through skincare professionals and select retail. Comparable to REJURAN Cosmetics as a science-led, professional-channel skincare brand pursuing the same hybrid professional/retail consumer pattern.
- SkinCeuticals (L'Oréal): SkinCeuticals is L'Oréal's medical-grade skincare brand sold through Sephora, physicians, and med-spas. Comparable to REJURAN Cosmetics as a clinical-claim derma-cosmetic SKU already anchored in Sephora's medical-grade skincare assortment that REJURAN is joining.
- Merz Aesthetics: Merz Aesthetics markets injectables (Belotero, Radiesse) and medical skincare lines globally. Comparable to PharmaResearch as a diversified aesthetics incumbent competing in HA fillers and regenerative/collagen-stimulating injectables in the same physician channels.
- LG Chem Life Sciences: LG Chem has a sizable life sciences division producing aesthetic fillers (e.g., YVOIRE), biologics, and specialty pharma. Comparable to PharmaResearch as a broader Korean player operating in regenerative/aesthetic pharmaceuticals with greater scale and capital resources.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PharmaResearch Products social profiles
Digital presencePharmaResearch Products compliance and trust
Trust signalCompliance1 record
PharmaResearch Products financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaResearch Products leadership team
Management profileNumber of profiles
Profiles2 records
PharmaResearch Products subsidiaries and ownership
Company hierarchySubsidiaries2 records
PharmaResearch Products funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaResearch Products M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaResearch Products
What does PharmaResearch Products do?
PharmaResearch Products is a biopharmaceutical company that develops, manufactures, and sells PDRN-based regenerative medicine products using its proprietary DNA Optimizing Technology (DOT) platform. Its commercial portfolio includes the REJURAN line of PN-based skin booster injectables for medical aesthetic practitioners and the REJURAN Cosmetics derma-cosmetic consumer skincare line featuring c-PDRN-based ampoules, creams, and masks sold through retail and e-commerce channels. The company is also developing PRD-101, a next-generation nano anticancer drug candidate leveraging the DOT drug delivery platform that received FDA IND clearance for Phase 1 clinical trials.
Is PharmaResearch Products a public or private company?
PharmaResearch Products is a private company. It is classified as public and is currently operating.
When was PharmaResearch Products founded?
PharmaResearch Products was founded in 1993. It employs 101 to 250 people.
Where is PharmaResearch Products based?
PharmaResearch Products is headquartered in Gangneung, South Korea, in the Asia region.
How does PharmaResearch Products make money?
Three revenue lines are on record. PDRN Injectables are the primary driver. The others are REJURAN Cosmetics (Consumer Skincare) and nano Anticancer Drug (PRD-101).
Who are PharmaResearch Products's main competitors?
Direct peers on record are Laboratoires VIVACY, Hugel, Inc., Medytox and Teoxane Laboratories. Broad incumbents are Galderma, AbbVie (Allergan Aesthetics), Dermalogica (Unilever), SkinCeuticals (L'Oréal), Merz Aesthetics and LG Chem Life Sciences.
Does PharmaResearch Products have an API?
No public API is recorded for PharmaResearch Products.
What industry is PharmaResearch Products in?
PharmaResearch Products's product category is Regenerative Medicine Pharmaceuticals and Derma-Cosmetics. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 3254 and its SIC code is 2834.